Myrobalan Therapeutics Names Grant Bogle to Board of Directors
2024年7月29日 - 8:00PM
ビジネスワイヤ(英語)
Board strengthened by addition of financial,
operational, and leadership expertise
Additional $9M in capital raised through
subsequent Series A closing involving new investors
Myrobalan Therapeutics, a biotechnology company developing novel
oral small-molecule therapies to repair damage and restore brain
function in high-unmet need central nervous system (CNS)
conditions, announces the appointment of Mr. Grant C. Bogle to its
Board of Directors. Mr. Bogle is a seasoned biotech executive with
over three decades of operational experience in the biopharma
industry and a strong focus on financial strategy, business
development, corporate governance, and general management. The
announcement comes approximately one month after the company raised
an additional $9 million from three new investors through a
subsequent closing of its Series A round, bringing total Series A
funding to $33 million. The additional capital empowers the company
to advance its lead CSF1R inhibitor program through first-in-human
clinical testing and its demyelination-targeting GPR17 program
through IND-enabling studies.
“Grant is a highly accomplished life sciences executive who has
overseen the growth, commercialization, and sale of multiple
successful biotechnology companies. I am thrilled to welcome him to
our Board of Directors,” said Dr. Jing Wang, Chief Executive
Officer of Myrobalan Therapeutics. “Grant's financial, operational,
and leadership experience will be an invaluable asset to Myrobalan
as we deploy capital to fuel our next phase of growth and progress
our pipeline into the clinic.”
Mr. Bogle was formerly Chief Executive Officer at Epizyme, Inc.,
a Boston-based biotechnology company that developed TAZVERIK™
(tazemetostat), an FDA-approved oral EZH2 inhibitor for the
treatment of relapsed/refractory follicular lymphoma. He assumed
the CEO position in 2021 after having served on the Epizyme Board
of Directors since 2019, and subsequently oversaw the 2022
acquisition of the company by Ipsen. Prior to that, Grant was
senior vice president and chief commercial officer of TESARO, a
publicly traded oncology company, which was acquired by
GlaxoSmithKline in 2018 for $5.1 billion. Earlier, he served as
senior vice president of pharmaceutical and biotech solutions at
McKesson Specialty Health/U.S. Oncology, and was a senior executive
at Millennium Pharmaceuticals, Viacord, Roche, and Knoll
Pharmaceutical Company.
"It is a privilege to join Myrobalan's Board of Directors at
such an exciting time in the company's journey," said Mr. Bogle.
"Myrobalan's clear focus on central nervous system diseases, strong
pipeline of brain-penetrant oral small molecule programs, and rapid
R&D progress give this company tremendous potential to advance
first-in-class and best-in-class therapeutics. I am eager to
contribute my expertise and to work alongside this talented team to
advance our mission of delivering transformative treatments to
patients with severe CNS disorders."
Mr. Bogle also serves on the board of the American School for
the Deaf, the oldest permanent school for the deaf in the United
States. He holds a B.A. in economics from Dartmouth College, an MBA
from Columbia Business School, and served as a fellow in the 2020
cohort of the Advanced Leadership Initiative at Harvard
University.
About Myrobalan Therapeutics
Myrobalan Therapeutics is a preclinical stage biotechnology
company headquartered in Medford, Massachusetts, with a focus on
developing oral neurorestorative therapies aimed at reversing key
pathologies underlying brain dysfunctions and CNS conditions.
Myrobalan applies deep knowledge of neurological processes such as
demyelination and neuroinflammation, and innovative drug discovery
tools, to create highly selective and brain-penetrant therapeutic
candidates that are uniquely positioned for treating CNS conditions
with significant unmet medical need. Myrobalan’s pipeline of novel
remyelination and anti-neuroinflammation programs are being
advanced with the strategic support of renowned institutional
co-founders. Myrobalan is committed to a transformed future in
which patients with degenerative CNS conditions can access safe and
effective medicines offering restorative potential. For more
information on Myrobalan Therapeutics, visit our website at
myrotx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725463217/en/
Justin Chen Ten Bridge Communications
jchen@tenbridgecommunications.com